Exenatide
- Generic Name
- Exenatide
- Brand Names
- Bydureon, Byetta
- Drug Type
- Biotech
- CAS Number
- 141758-74-9
- Unique Ingredient Identifier
- 9P1872D4OL
- Background
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations. Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
- Indication
Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. An extended-release formulation is available which is indicated in patients ≥10 years old, while the immediate-acting formulation is approved only for adult patients.
- Associated Conditions
- Type 2 Diabetes Mellitus
Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Target Recruit Count
- 40
- Registration Number
- NCT02847403
- Locations
- 🇮🇹
Endocrinology Unit, Parma, Italy
🇮🇹Center for Cognitive Disorders and Dementia AUSL of Parma and University of Parma, Parma, Italy
The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers
- First Posted Date
- 2016-07-20
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Christina Kruuse
- Target Recruit Count
- 30
- Registration Number
- NCT02838589
- Locations
- 🇩🇰
Department of Neurology, Herlev-Gentofte Hospital, Herlev, Denmark
The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Christina Kruuse
- Target Recruit Count
- 30
- Registration Number
- NCT02829502
- Locations
- 🇩🇰
Department of Neurology, Herlev-Gentofte Hospital, Herlev, Denmark
A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 5
- Registration Number
- NCT02802514
- Locations
- 🇺🇸
GSK Investigational Site, Boston, Massachusetts, United States
Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Uppsala University
- Target Recruit Count
- 44
- Registration Number
- NCT02794402
- Locations
- 🇦🇹
Department of Pediatrics, Salzburg State Hospital, Paracelsus Medical University, Salzburg, Austria
🇸🇪Uppsala University Hospital, Uppsala, Sweden
An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 4
- Registration Number
- NCT02793154
- Locations
- 🇺🇸
GSK Investigational Site, Dallas, Texas, United States
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Insulin glargine/lixisenatide fixed ratio combination
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 514
- Registration Number
- NCT02787551
- Locations
- 🇺🇸
Investigational Site Number 8400033, Baltimore, Maryland, United States
🇺🇸Investigational Site Number 8400079, Albany, New York, United States
🇺🇸Investigational Site Number 8400019, Columbus, Ohio, United States
Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes
- Conditions
- Diabetes Mellitus, Type 1Hypoglycemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2018-04-12
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT02735031
- Locations
- 🇳🇱
Radboud university medical centre, Nijmegen, Netherlands
Gut Hormones in Obesity, Nicotine and Alcohol Dependence
- Conditions
- AlcoholismSmoking CessationObesity
- Interventions
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2020-02-13
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 95
- Registration Number
- NCT02690987
- Locations
- 🇬🇧
Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College London, Hammersmith Hospital, London, United Kingdom
Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 92
- Registration Number
- NCT02690883
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.